Antiangiogene Präkonditionierung vor Keratoplastik

Zusammenfassung

Einleitung: Darstellung antiangiogener und antilymphangiogener Therapiestrategien zur Verbesserung des Transplantatüberlebens nach Keratoplastik.

Methoden: PubMed-Literaturübersicht und eigene klinische und experimentelle Daten.

Ergebnisse: Es gibt 3 Ansätze zur Verbesserung des Transplantatüberlebens durch antiangiogene Therapie: (a) primäre Prävention durch Verhinderung der Angiogenese im Rahmen kornealer Erkrankungen, (b) sekundäre Prävention durch Regression vorhandener stromaler kornealer Gefäße vor der Transplantation und (c) tertiäre Prävention durch Hemmung der postoperativen Neovaskularisation.

Schlussfolgerung: Moderne antiangiogene und antilymphangiogene topische Therapien scheinen in der Lage zu sein, das Transplantatüberleben bei perforierender Keratoplastik gerade im Hochrisikobereich zu verbessern.

Abstract

Purpose: The aim of this study is to describe novel therapeutic concepts to promote graft survival in high-risk keratoplasty by targeting (lymph)angiogenesis in the transplant context.

Methods: A PubMed literature search and our own clinical and experimental data are evaluated.

Results: There are three options for anti(lymph)angiogenic preconditioning: a) primary prevention of neovascularisation during the disease process, b) secondary prevention by regressing established blood vessels prior to transplantation and (c) tertiary prevention through inhibition of post-keratoplasty neovascularisation.

Conclusion: Modern topical anti(lymph)angiogenic therapies seem to be able to reduce the risk of graft rejection especially in high-risk keratoplasty.

Schlüsselwörter

(Lymph)Angiogenese - Anatomie - Pathologie - (Hochrisiko)Keratoplastik - Kornea - Regression

Key words

(lymph)angiogenesis - anatomy - pathology - (high-risk) keratoplasty - cornea - regression

• Literatur

• 1 Cursiefen C, Chen L, Saint-Geniez M et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 2006; 103: 11405-11410
• 2 Chang JH, Gabison EE, Kato T et al. Corneal neovascularization. Curr Opin Ophthalmol 2001; 12: 242-249
• 3 Bock F, Koenig Y, Dietrich T et al. Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 2007; 104: 336-344
• 4 Koenig Y, Bock F, Horn F et al. Short- and long-term safety profile and efficacy of topical Bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1375-1382
• 5 Regenfuss B, Bock F, Cursiefen C. Corneal angiogenesis and lymphangiogenesis. Curr Opin Allergy Clin Immunol 2012; 125: 548-554
• 6 Altenburger AE, Bachmann B, Seitz B et al. Morphometric analysis of postoperative corneal neovascularization after high-risk keratoplasty: herpetic versus non-herpetic disease. Graefes Arch Clin Exp Ophthalmol 2012; 250: 1663-1671
• 7 Koenig Y, Bock F, Kruse FE, Stock K et al. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea 2012; 31: 887-892
• 8 Cloutier F, Lawrence M, Goody R et al. Anti-angiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease following topical administration. Invest Ophthalmol Vis Sci 2012; 53: 1195-1203
• 9 Cursiefen C, Rummelt C, Küchle M et al. Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 2003; 87: 101-106
• 10 Bachmann B, Taylor RS, Cursiefen C. The association between corneal neovascularization and visual acuity: a systematic review. Acta Ophthalmol 2013; 91: 12-19
• 11 Cursiefen C, Colin J, Dana R et al. Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol 2012; 96: 3-9
• 12 Hos D, Regenfuss B, Bock F et al. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis. Invest Ophthalmol Vis Sci 2011; 52: 5778-5785
• 13 Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010; 117: 1300-1305
• 14 Dietrich T, Bock F, Yuen D et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 2010; 184: 535-539
• 15 Cursiefen C, Heindl LM. Perspectives of deep anterior lamellar keratoplasty. Ophthalmologe 2011; 108: 833-839
• 16 Steven P, Bock F, Hüttmann G et al. Intravital two-photon microscopy of immune cell dynamics in corneal lymphatic vessels. PLoS One 2011; 6: e26253
• 17 Bock F, Koenig Y, Kruse F et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008; 246: 281-284
• 18 Cursiefen C, Bock F, Horn FK et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: Interim results of a randomized phase II trial. Ophthalmology 2009; 116: 1630-1637
• 19 Hos D, Saban DR, Bock F et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol 2011; 129: 445-452
• 20 Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 2000; 41: 2148-2153
• 21 Cursiefen C, Wenkel H, Martus P et al. Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 2001; 239: 514-521
• 22 Cursiefen C, Maruyama K, Liu Y et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004; 45: 2666-2673
• 23 Bachmann B, Bock F, Wiegand S et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 2008; 126: 71-77
• 24 Bachmann BO, Luetjen-Drecoll E, Bock F et al. Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol 2009; 93: 1075-1080
• 25 Cursiefen C, Kruse FE. [DMEK: Descemet membrane endothelial keratoplasty]. Ophthalmologe 2010; 107: 370-376